Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to -$623000.0.

  • Fennec Pharmaceuticals' Net Income towards Common Stockholders rose 8909.12% to -$623000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 58835.47%. This contributed to the annual value of -$436000.0 for FY2024, which is 9728.26% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Net Income towards Common Stockholders is -$623000.0, which was up 8909.12% from -$3.2 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $12.9 million during Q1 2024, with a 5-year trough of -$10.3 million in Q4 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$4.1 million (2021), whereas its average is -$3.4 million.
  • The largest annual percentage gain for Fennec Pharmaceuticals' Net Income towards Common Stockholders in the last 5 years was 31658.0% (2024), contrasted with its biggest fall of 22247.32% (2024).
  • Fennec Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$4.2 million in 2021, then tumbled by 145.15% to -$10.3 million in 2022, then surged by 74.66% to -$2.6 million in 2023, then surged by 42.67% to -$1.5 million in 2024, then soared by 58.49% to -$623000.0 in 2025.
  • Its Net Income towards Common Stockholders stands at -$623000.0 for Q3 2025, versus -$3.2 million for Q2 2025 and -$1.2 million for Q1 2025.